Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC
Jarushka Naidoo, Scott Antonia, Yi‐Long Wu, Byoung Chul Cho, Piruntha Thiyagarajah, Helen Mann, Michael Newton, Corinne Faivre‐Finn
Topics & Concepts
DurvalumabMedicineChemoradiotherapyOncologyInternal medicinePost-hoc analysisSubgroup analysisRegimenStage (stratigraphy)Overall survivalImmunotherapyNivolumabCancerConfidence intervalBiologyPaleontologyCancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsColorectal Cancer Treatments and Studies